Research and Development

Research is in our DNA.
The future is in our research.

Research is part of Eurospital’s DNA, placing the company at the heart of a major network of international universities and research centers.
Sustainable innovation is a family tradition that began in the 1950s and has been passionately carried forward by three generations — a testament to our strong commitment to providing customers, patients, and consumers with new solutions to improve their quality of life.

Leaders in Diagnostic Research

Eurospital is one of the few Italian companies with an in-house Research & Development (R&D) department, equipped with dedicated laboratories for Diagnostics. Its R&D function is among the most dynamic in Italy in terms of the number of research projects and the level of investment.

Eurospital has become an international benchmark for the development of in vitro diagnostic products for various diseases — some of which are patent-protected, such as in the fields of sepsis and celiac disease. The company is also a founding member of the Consortium for the Centre of Molecular Biomedicine (CBM), alongside major universities and globally renowned research centers.

The R&D team brings together expertise in chemistry, biology, medicine, IT, and instrumentation. It collaborates daily with a global network of leading clinicians, universities, and international research centers — a synergy that has enabled the development of important projects, the creation of new ideas, products, and services, while strengthening Eurospital’s business and contributing to scientific progress.

Innovations in the Pharmaceutical Market

Looking toward a sustainable future, Eurospital has developed successful products and services by implementing winning ideas to diversify its pharmaceutical and special nutrition portfolio (gluten-free and low-protein), while identifying new business development opportunities through strategic partnerships.

Always attentive to emerging market needs, shaped by evolving social dynamics and lifestyles, Eurospital continuously strives to expand its offering for pharmacies and parapharmacies, providing safe products and top-quality services. The company has renewed its efforts in R&D, contract manufacturing, marketing, communication, and customer support across a wide range of prescription and over-the-counter (OTC) drugs, medical devices, cosmetics, and food supplements.

In 2024, Eurospital also established the new Special Nutrition Division, which now includes gluten-free foods — designed for individuals with celiac disease — and low-protein products, essential for supplementing the diets of patients with chronic kidney disease.

Thanks to its long-standing expertise in the field, Eurospital remains a trusted reference point for pharmacists, offering innovative solutions to improve people’s quality of life.

Area Download

“Sanitization, social distancing and exploitation of IT technology”
Announcement POR FESR 2014-2020 – Line of action 2.3.c.1
Download (PDF – 101KB)

“Integrated system of diagnostic devices for the determination of fecal elastase-1”
Advance notice – POR FESR 2021–2027. Incentives for companies engaged in collaborative industrial research and experimental development.
AREAS OF SPECIALISATION AND DEVELOPMENT PATHWAYS OF THE REGIONAL SMART SPECIALISATION STRATEGY 2021–2027 (S4) – CALL 2022
Download (PDF – 1,36MB) – ITA

PR FESR 2021–2027 Friuli Venezia Giulia Region
FUNDING FOR THE USE OF RENEWABLE ENERGY
Call for Action b2.1 “Non-repayable grants for the use of renewable energy in businesses” – CALL 2023
Download (PDF – 538 KB) – ITA